Stem Cell Transplant or Cellular Therapy

- Allogeneic
  - AML/MDS/ALL
    - MDS Only
    - AML Only
    - AML/MDS Only
    - AML/MDS/ALL
  - Multiple Myeloma
  - High Risk
  - Severe Aplastic Anemia
  - Multiple Diseases

IRB#10146 Compares reduced intensity allogeneic stem cell transplant to hypomethylating therapy or best supportive care in patients aged 50-75 with intermediate-2 and high-risk myelodysplastic syndrome.

IRB#17622 Testing the drug Gilteritinib with a placebo in AML with a FLT3/ITD mutation after allogeneic transplant.

IRB#16995 Tests the drug Pro140 compared to placebo to prevent Graft vs. Host Disease in AML and MDS patients undergoing allogeneic stem cell transplants.

IRB#16189 Phase 1/phase 2 study of ProTmune evo mobilized peripheral blood cells.

IRB#11907 BEAM Conditioning for Allogeneic Hematopoietic Transplant for Sibling or Unrelated donors.

IRB#16943 BMT CTN phase II study of ATG-based conditioning regimens for haploidentical and cord blood transplants.

IRB#16982 Donor T-Cell infusion for adults with recurrent minimal residual disease post HSCT.

IRB#9375 Phase 1-2 BPK-501 T Cells after Partially Mismatched, Related Donor T Cell-Depleted Stem Cell Transplant.

http://www.ohsu.edu/research/rda/so/knight.php